Lung Cancer Flashcards
Describe the TNM stage
Tumor -5cm RLL
N - right paratracheal and sub carina
M -0
T2b- 4-5cm (inclusive)
N2- ipsilateral mediastinal or sub carina
M-O
Stage 3A
Stage this tumor
T- 4.2cm right LL with destruction of adjacent rib
T3- tumor involving the chest wall, pericardium, phrenic nerve, satellite module in same lobe or >5-7com
n0
M0
Stage 2B
Stage this NSCLC
T- 3.7cm RLL tumor with right mainstem bronchus involvement
N -contralateral mediastinum
M0
T2a- involves bronchus but not carina (carina =t4), and T2a =3-4cm
N3- contralateral mediastinal
M-0
Stage 3b
What is considered adequate in shuttle walk test
> 25 shuttles
In the national lung cancer screening trial (NLST) what was the difference in radiation dose? What was considered a positive screen?
Annual lose dose CT x 3 versus chest X-ray
1.5 mSv used compared to average of 8
Positive screen: non calcified solid nodule > 4mm, new adenopathy or effusion
In the national lung cancer screening trial (NLST) what we’re the results of annual screening?
Relative reduction of 20%
NNT = 320
Lots of false positives
What is the recommendation for lung cancer screening?
Annual low dose CT scan
Age 55-74
With a 30 pack year hx who smoke or quit <15 yrs ago
3 consecutive years
What are the cutoffs for PFT before proceeding to lung cancer surgery?
Post operative Fev1 or DLCO < 60% predicted—> proceed
30-60%—-> shuttle walk (>400m)
<30% cpet —-> >10ml/kg/min
List the components of the thoracic RCRI
Pneumonectomy- 1.5
Previous Cad- 1.5
Stroke or tia- 1.5
Gfr< 30 - 1 pt
Score >=2 means cardiac consultation required
What are 3 ways to reduce perioperative risk and improve pulmonary disability
- Smoking cessation
2 pulmonary rehabilitation - Concomitant lung volume reduction surgery
What are three tyrosine kinase inhibitors that target the EGFR mutation?
Gefitinibb, erlotinib, afatinib
List 5 risk factors for lung cancer aside from smoking
Asbestos Silicosis Radon, uranium mining Genetic HIV
List an adjuvant therapy for EGFR+ lung cancer
Osimertinib
List two examples of immunotherapy directed at PDL-1
Durvalumab
Pembrolizumab